Background: Whether interleukin (IL)-8, IL-10, and IL-18 polymorphisms influence predisposition of inflammatory bowel disease (IBD) remains uncertain. Objectives: The authors conducted a meta-analysis to explore relationships between IL-8, IL-10, or IL-18 polymorphisms and predisposition of IBD by merging the results of eligible literatures. Methods: A thorough literature search in MEDLINE, Embase, Wanfang, VIP, and CNKI was conducted by the authors to identify eligible literatures, and 33 literatures were finally selected for merged analyses. Results: We found that genotypic frequencies of IL-8 rs4073, IL-10 rs1800871, IL-10 rs1800872, and IL-10 rs1800896 polymorphisms among cases with IBD and population-based controls differed significantly. Moreover, we found that genotypic frequencies of IL-8 rs4073, IL-10 rs1800871, and IL-18 rs1946518 polymorphisms among cases with IBD and population-based controls of Asian origin differed significantly, whereas genotypic frequency of IL-10 rs1800896 polymorphism among cases with IBD and population-based controls of Caucasian origin also differed significantly. Furthermore, genotypic frequency of IL-18 rs187238 polymorphism among cases with Crohn’s disease (CD) and population-based controls also differed significantly. Conclusions: The present meta-analysis shows that IL-8 rs4073, IL-10 rs1800871, IL-10 rs1800872, IL-10 rs1800896, and IL-18 rs1946518 polymorphisms may influence predisposition of IBD. Furthermore, IL-18 rs187238 polymorphism may influence predisposition of CD, but not predisposition of ulcerative colitis.

1.
Burisch
J
,
Munkholm
P
.
The epidemiology of inflammatory bowel disease
.
Scand J Gastroenterol
.
2015
;
50
(
8
):
942
51
.
2.
Zhang
YZ
,
Li
YY
.
Inflammatory bowel disease: pathogenesis
.
World J Gastroenterol
.
2014
;
20
(
1
):
91
9
.
3.
Ko
JK
,
Auyeung
KK
.
Inflammatory bowel disease: etiology, pathogenesis, and current therapy
.
Curr Pharm Des
.
2014
;
20
(
7
):
1082
96
.
4.
Mitsuyama
K
,
Niwa
M
,
Takedatsu
H
,
Yamasaki
H
,
Kuwaki
K
,
Yoshioka
S
, et al.
Antibody markers in the diagnosis of inflammatory bowel disease
.
World J Gastroenterol
.
2016
;
22
(
3
):
1304
10
.
5.
Parkes
M
.
Evidence from genetics for a role of autophagy and innate immunity in IBD pathogenesis
.
Dig Dis
.
2012
;
30
(
4
):
330
3
.
6.
Neurath
MF
.
Cytokines in inflammatory bowel disease
.
Nat Rev Immunol
.
2014
;
14
(
5
):
329
42
.
7.
Bouguen
G
,
Chevaux
JB
,
Peyrin-Biroulet
L
.
Recent advances in cytokines: therapeutic implications for inflammatory bowel diseases
.
World J Gastroenterol
.
2011
;
17
(
5
):
547
56
.
8.
Magyari
L
,
Kovesdi
E
,
Sarlos
P
,
Javorhazy
A
,
Sumegi
K
,
Melegh
B
.
Interleukin and interleukin receptor gene polymorphisms in inflammatory bowel diseases susceptibility
.
World J Gastroenterol
.
2014
;
20
(
12
):
3208
22
.
9.
Ferguson
LR
,
Shelling
AN
,
Browning
BL
,
Huebner
C
,
Petermann
I
.
Genes, diet, and inflammatory bowel disease
.
Mutat Res
.
2007
;
622
(
1–2
):
70
83
.
10.
Moher
D
,
Liberati
A
,
Tetzlaff
J
,
Altman
DG
;
PRISMA group
.
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
.
Int J Surg
.
2010
;
8
(
5
):
336
41
.
11.
Stang
A
.
Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses
.
Eur J Epidemiol
.
2010
;
25
(
9
):
603
5
.
12.
Smith
AJ
,
Humphries
SE
.
Cytokine and cytokine receptor gene polymorphisms and their functionality
.
Cytokine Growth Factor Rev
.
2009
;
20
(
1
):
43
59
.
13.
Thompson
SR
,
Humphries
SE
.
Interleukin-18 genetics and inflammatory disease susceptibility
.
Genes Immun
.
2007
;
8
(
2
):
91
9
.
14.
Liu
TC
,
Stappenbeck
TS
.
Genetics and pathogenesis of inflammatory bowel disease
.
Annu Rev Pathol
.
2016
;
11
:
127
48
.
15.
Turpin
W
,
Goethel
A
,
Bedrani
L
,
Croitoru Mdcm
K
.
Determinants of IBD heritability: genes, bugs, and more
.
Inflamm Bowel Dis
.
2018
;
24
(
6
):
1133
48
.
16.
Ye
BD
,
McGovern
DP
.
Genetic variation in IBD: progress, clues to pathogenesis, and possible clinical utility
.
Expert Rev Clin Immunol
.
2016
;
12
(
10
):
1091
107
.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.